Two previous meta-analyses published in 2018 and 2019, concluded that anti-IL-1 therapies can significantly decrease the level of HbA1c and CRP, and have mild hypoglycaemic effect on patients with T2DM (20, 21). The gene discussed is CRP; the disease is type 2 diabetes mellitus.